Novartis

China to pip U.S. researchers to the post on first CRISPR trial

UPDATED: FDA rejects Novartis’ biosim app for Amgen blockbuster

Novartis gains FDA panel thumbs up for Amgen Enbrel copy

Novartis cancer drug to be tested for Parkinson’s disease

FDA panel backs Amgen’s Humira copy, but don’t expect to see it anytime soon

Novartis taps Cure Forward for help identifying cancer trial participants

Genetic element dysregulation may exacerbate autoimmune diseases

Novartis goes bispecific with Xencor in up to $2.6B immuno-oncology deal

Novartis, Atlas Ventures back upstart IFM Therapeutics in $27M raise

Facebook, Napster billionaire Parker to fund first-ever CRISPR trial